Dataset Information

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

ABSTRACT: Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels ?10% at 3 months, <1% at 6 months, and ?0.1% from 12 months onward define optimal response, whereas >10% at 6 months and >1% from 12 months onward define failure, mandating a change in treatment. Similarly, partial cytogenetic response (PCyR) at 3 months and complete cytogenetic response (CCyR) from 6 months onward define optimal response, whereas no CyR (Philadelphia chromosome-positive [Ph+] >95%) at 3 months, less than PCyR at 6 months, and less than CCyR from 12 months onward define failure. Between optimal and failure, there is an intermediate warning zone requiring more frequent monitoring. Similar definitions are provided for response to second-line therapy. Specific recommendations are made for patients in the accelerated and blastic phases, and for allogeneic stem cell transplantation. Optimal responders should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.

SUBMITTER: Baccarani M

PROVIDER: S-EPMC4915804 | biostudies-other | 2013 Aug

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Baccarani Michele M Deininger Michael W MW Rosti Gianantonio G Hochhaus Andreas A Soverini Simona S Apperley Jane F JF Cervantes Francisco F Clark Richard E RE Cortes Jorge E JE Guilhot François F Hjorth-Hansen Henrik H Hughes Timothy P TP Kantarjian Hagop M HM Kim Dong-Wook DW Larson Richard A RA Lipton Jeffrey H JH Mahon François-Xavier FX Martinelli Giovanni G Mayer Jiri J Müller Martin C MC Niederwieser Dietger D Pane Fabrizio F Radich Jerald P JP Rousselot Philippe P Saglio Giuseppe G Saußele Susanne S Schiffer Charles C Silver Richard R Simonsson Bengt B Steegmann Juan-Luis JL Goldman John M JM Hehlmann Rüdiger R

Blood 20130626 6

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update recommendations made in 2009. We recommend as initial treatment imatinib, nilotinib, or dasatinib. Response is assessed with standardized real quantitative polymerase chain reaction and/or cytogenetics at 3, 6, and 12 months. BCR-ABL1 transcript levels ≤10% at 3 months, ...[more]

PMID: 23803709

Similar Datasets

Project description:The first treatment of chronic myeloid leukemia (CML) included spleen x-radiation and conventional drugs, mainly Busulfan and Hydroxyurea. This therapy improved the quality of life during the chronic phase of the disease, without preventing nor significantly delaying the progression towards advanced phases. The introduction of allogeneic stem cell transplantation (alloSCT) marked the first important breakthrough in the evolution of CML treatment, because about 50% of the eligible patients were cured. The second breakthrough was the introduction of human recombinant interferon-alfa, able to achieve a complete cytogenetic remission in 15% to 30% of patients, with a significant survival advantage over conventional chemotherapy. At the end of the last century, about 15 years ago, all these treatments were quickly replaced by a class of small molecules targeting the tyrosine kinases (TK), which were able to induce a major molecular remission in most of the patients, without remarkable side effects, and a very prolonged life-span. The first approved TK inhibitor (TKI) was Imatinib Mesylate (Glivec or Gleevec, Novartis). Rapidly, other TKIs were developed tested and commercialized, namely Dasatinib (Sprycel, Bristol-Myers Squibb), Nilotinib (Tasigna, Novartis), Bosutinib (Busulif, Pfizer) and Ponatinib (Iclusig, Ariad). Not all these compounds are available worldwide; some of them are approved only for second line treatment, and the high prices are a problem that can limit their use. A frequent update of treatment recommendations is necessary. The current treatment goals include not only the prevention of the transformation to the advanced phases and the prolongation of survival, but also a length of survival and of a quality of life comparable to that of non-leukemic individuals. In some patient the next ambitious step is to move towards a treatment-free remission. The CML therapy, the role of alloSCT and the promising experimental strategies are reviewed in the context of the new therapeutic goals.

Dataset Information

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Publications

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure